account_circleRecruiting

Cardiac surgery-associated acute kidney injury

Bayer Identifier:
22785
ClinicalTrials.gov Identifier:
NCT06772025
EudraCT Number:
Not Available
EU CT Number:
Not Available
A study to understand how cardiac surgery-associated acute kidney injury develops in participants who undergo heart surgery with the use of heart-lung machine

Trial purpose

Researchers are looking for a better way to treat and prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in people who undergo heart surgeries.
CSA-AKI is a common complication in people undergoing heart surgeries, where the kidneys stop working properly. CSA-AKI risk factors include older age and alongside diseases such as kidney disease and diabetes. Longer time with heart-lung machine during heart surgeries also increases the occurrence of CSA-AKI.

In this study, researchers want to better understand how CSA-AKI develops (also known as the mechanisms involved in the development of CSA-AKI) in people under heart surgeries, the presence of certain biomarkers in the body, especially with a focus on the early hours and days after the surgery. (A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.)
These biomarkers will be compared in participants who develop CSA-AKI within a week after heart surgery with the participants who do not develop CSA-AKI. The relationship with biomarkers will be determined by examining participants’ blood and urine samples before and after surgery.
This may help researchers better understand CSA-AKI, identify potential treatment targets and develop possible treatments to prevent CSA-AKI.

Participants in this study will be people who have heart surgery already scheduled by their own doctors and have a risk of developing CSA-AKI. Participants will not receive any treatment as part of this study. They will undergo the heart surgery and related medical processes as per their normal medical treatment and management.
Each participant will be in the study for up to 2 months. During the study, the doctors and their study team will:
• collect participants’ blood and urine samples before and after surgery
• assess participants’ medical records and test reports during hospitalization
• monitor overall health of the participants throughout the study

Key Participants Requirements

Sex

All

Age

18 - N/A
  • - Participant must be at least 18 years of age at the time of signing the informed consent form (ICF).
    - Participants who are scheduled for hospital admission for any of the following cardiovascular surgery interventions, alone or in combination, involving cardiopulmonary bypass (CPB):
     -- Aortic, mitral, or tricuspid valve surgery (repair or replacement)
     -- Aortic surgery
     -- ≥3 coronary artery bypass grafts
    - Participant with: chronic kidney disease (CKD): 30 ≤ estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m^2
  • - Emergency surgery situation
    - Anemia – hemoglobin <10 g/dL
    - Clinical signs of systemic infection or other infection requiring anti-infective treatment (viral, bacterial, fungal, parasitic; single-dose prophylaxis allowed)
    - Systemic immunosuppressive or anti-inflammatory treatment including corticosteroids >10 mg prednisolone equivalent/day
    - Any anti-cancer treatment within 3 months (e.g. immunotherapy, chemotherapy, radiotherapy)
    - Major surgery within 2 months
    - AKI within the last month
    - Prior renal transplants or RRT
    - Planned use of contrast media within 5 days prior to surgery or during surgery
    - Patient included in an interventional clinical trial involving a pharmacological intervention
    - Any reason that would make participation unadvisable, at the discretion of the investigator.
    - Autoimmune disorders such as anti-glomerular basement membrane (anti-GBM) diseases, systemic lupus erythematosus, chronic rheumatic heart diseases, acute rheumatic heart pericarditis, endocarditis, myocarditis, rheumatic mitral valve diseases, rheumatic aortic valve diseases

Trial summary

Enrollment Goal
200
Trial Dates
February 2025 - August 2026
Phase
N/A
Could I Receive a placebo
No
Products
No Drug
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Recruiting
Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW)Bad Oeynhausen, 32545, Germany
Not yet recruiting
Royal Papworth Hospital NHS Foundation Trust | Royal Papworth Hospital - Cardiac SurgeryCambridge, CB2 0AY, United Kingdom
Not yet recruiting
Guy’s and St Thomas’ NHS Foundation Trust, Harefield Hospital - CardiologyHarefield, UB9 6JH, United Kingdom

Primary Outcome

  • Number of participants with CSA-AKI until Day 3 post-surgery
    CSA-AKI: cardiac surgery-associated acute kidney injury
    date_rangeTime Frame:
    Up to 3 days post surgery

Secondary Outcome

  • Observed values of pre-defined biomarkers overall and by CSA-AKI outcome
    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury
    date_rangeTime Frame:
    Up to 7 days post surgery
  • Change from baseline of pre-defined biomarkers overall and by CSA-AKI outcome
    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury
    date_rangeTime Frame:
    Up to 7 days post surgery
  • Ratio to baseline of pre-defined biomarkers overall and by CSA-AKI outcome
    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury
    date_rangeTime Frame:
    Up to 7 days post surgery

Trial design

Methodology study in patients undergoing cardiac surgery with cardiopulmonary bypass to investigate mechanisms involved in cardiac surgery-associated acute kidney injury.
Trial Type
Interventional
Intervention Type
Other
Trial Purpose
Basic Science
Allocation
N/A
Blinding
N/A
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here to find further information and, after study completion, the study results according to Bayer's transparency standards.